BRPI0807749A2 - Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos. - Google Patents

Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos.

Info

Publication number: BRPI0807749A2
Authority: BR; Brazil
Prior art keywords: cutaneal; chronic; acute; prevention; improvement
Prior art date: 2007-02-28

Application number

BRPI0807749-5A2A

Other languages

English (en)

Inventor

Jakob Felding

Simon Feldbaek Nielsen

Jens Christian Hojland Larsen

Bollu Ravindra Babu

Original Assignee

Leo Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-28

Filing date

2008-02-26

Publication date

2014-06-17

2008-02-26 Application filed by Leo Pharma As filed Critical Leo Pharma As

2014-06-17 Publication of BRPI0807749A2 publication Critical patent/BRPI0807749A2/pt

2021-01-05 Publication of BRPI0807749B1 publication Critical patent/BRPI0807749B1/pt

2022-09-06 Publication of BRPI0807749B8 publication Critical patent/BRPI0807749B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0807749A 2007-02-28 2008-02-26 composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos BRPI0807749B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US90384907P	2007-02-28	2007-02-28
US60/903849		2007-02-28
US94684907P	2007-06-28	2007-06-28
US60/946849		2007-06-28
PCT/DK2008/000080 WO2008104175A2 (en)	2007-02-28	2008-02-26	Novel phosphodiesterase inhibitors

Publications (3)

Publication Number	Publication Date
BRPI0807749A2 true BRPI0807749A2 (pt)	2014-06-17
BRPI0807749B1 BRPI0807749B1 (pt)	2021-01-05
BRPI0807749B8 BRPI0807749B8 (pt)	2022-09-06

Family

ID=39415336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0807749A BRPI0807749B8 (pt)	2007-02-28	2008-02-26	composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos

Country Status (21)

Country	Link
US (1)	US8338431B2 (pt)
EP (1)	EP2114951B9 (pt)
JP (1)	JP5501770B2 (pt)
KR (1)	KR101571654B1 (pt)
AU (1)	AU2008221121B2 (pt)
BR (1)	BRPI0807749B8 (pt)
CA (1)	CA2676933C (pt)
CY (1)	CY1115227T1 (pt)
DK (1)	DK2114951T3 (pt)
ES (1)	ES2478670T3 (pt)
HR (1)	HRP20140585T1 (pt)
IL (1)	IL200153A (pt)
MX (1)	MX2009009238A (pt)
MY (1)	MY150075A (pt)
NZ (1)	NZ578804A (pt)
PL (1)	PL2114951T3 (pt)
PT (1)	PT2114951E (pt)
RS (1)	RS53407B (pt)
RU (1)	RU2495043C2 (pt)
SI (1)	SI2114951T1 (pt)
WO (1)	WO2008104175A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112012015449B1 (pt)	2009-12-22	2021-09-28	Leo Pharma A/S	Suspensão de monoidrato de calcipotriol, e, processo para preparar nanocristais de monoidrato de calcipotriol
US20120322776A1 (en)	2009-12-22	2012-12-20	Leo Pharma A/S	Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
CN102770121B (zh)	2009-12-22	2014-10-15	利奥制药有限公司	包含溶剂混合物和维生素d衍生物或类似物的药物组合物
NZ603895A (en)	2010-06-24	2014-10-31	Leo Pharma As	Novel phosphodiesterase inhibitors
WO2013122855A1 (en) *	2012-02-14	2013-08-22	University Of Rochester	Methods of increasing lymphatic transport
CA2875421A1 (en) *	2012-06-04	2013-12-12	Chiesi Farmaceutici S.P.A.	Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9855285B2 (en)	2012-11-30	2018-01-02	Leo Pharma A/S	Method of inhibiting the expression of IL-22 in activated T-cells
RU2697251C2 (ru) *	2014-06-23	2019-08-13	Лео Фарма А/С	Способы получения 1, 3-бензодиоксольных гетероциклических соединений
JP6742348B2 (ja)	2015-06-19	2020-08-19	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としてのジアミド大員環
CN114085234B (zh)	2015-12-18	2024-12-17	联合疗法公司	用于制备1,3-苯并间二氧杂环戊烯杂环化合物的方法
ES2875128T3 (es) *	2016-12-12	2021-11-08	Union Therapeutics As	Pirazoloazepin-8-onas sustituidas y su uso como inhibidores de la fosfodiesterasa
CN110167944B (zh) *	2016-12-12	2024-08-23	联合疗法公司	取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途
EP3551634B1 (en) *	2016-12-12	2021-03-31	Leo Pharma A/S	Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors
KR102676384B1 (ko) *	2017-06-20	2024-06-20	유니온 테라퓨틱스 에이/에스	1,3-벤조디옥솔 헤테로시클릭 화합물의 제조방법
TW201919682A (zh)	2017-08-08	2019-06-01	西班牙商阿爾米雷爾有限公司	活化Ｎｒｆ２路徑的新穎化合物
DK3724196T3 (da)	2017-12-15	2023-01-16	Union Therapeutics As	Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
GB202306662D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Dosage regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9507297D0 (en)	1995-04-07	1995-05-31	Rh Ne Poulenc Rorer Limited	New composition of matter
US6514996B2 (en)	1995-05-19	2003-02-04	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of benzofuran or benzodioxole
AU705690B2 (en) *	1995-05-19	1999-05-27	Kyowa Hakko Kogyo Co. Ltd.	Oxygen-containing heterocyclic compounds
TR199802386T2 (xx) *	1996-05-20	1999-02-22	Darwin Discovery Limited	Benzofuran karboksamidler ve bunlar�n terap�tik kullan�m�.
WO1998008850A1 (en) *	1996-08-28	1998-03-05	The Procter & Gamble Company	Spirocyclic metalloprotease inhibitors
WO1998022455A1 (en)	1996-11-19	1998-05-28	Kyowa Hakko Kogyo Co., Ltd.	Oxygenic heterocyclic compounds
JP4219554B2 (ja) *	1997-10-01	2009-02-04	協和発酵キリン株式会社	ベンゾフラン誘導体

2008
- 2008-02-26 KR KR1020097018073A patent/KR101571654B1/ko active Active
- 2008-02-26 RS RS20140365A patent/RS53407B/sr unknown
- 2008-02-26 RU RU2009135810/04A patent/RU2495043C2/ru active
- 2008-02-26 MY MYPI20093168A patent/MY150075A/en unknown
- 2008-02-26 ES ES08706922.5T patent/ES2478670T3/es active Active
- 2008-02-26 WO PCT/DK2008/000080 patent/WO2008104175A2/en not_active Ceased
- 2008-02-26 NZ NZ578804A patent/NZ578804A/en not_active IP Right Cessation
- 2008-02-26 HR HRP20140585AT patent/HRP20140585T1/hr unknown
- 2008-02-26 BR BRPI0807749A patent/BRPI0807749B8/pt not_active IP Right Cessation
- 2008-02-26 JP JP2009551915A patent/JP5501770B2/ja not_active Expired - Fee Related
- 2008-02-26 US US12/528,649 patent/US8338431B2/en active Active
- 2008-02-26 PT PT87069225T patent/PT2114951E/pt unknown
- 2008-02-26 SI SI200831224T patent/SI2114951T1/sl unknown
- 2008-02-26 DK DK08706922.5T patent/DK2114951T3/da active
- 2008-02-26 CA CA2676933A patent/CA2676933C/en active Active
- 2008-02-26 MX MX2009009238A patent/MX2009009238A/es active IP Right Grant
- 2008-02-26 PL PL08706922T patent/PL2114951T3/pl unknown
- 2008-02-26 AU AU2008221121A patent/AU2008221121B2/en not_active Ceased
- 2008-02-26 EP EP08706922.5A patent/EP2114951B9/en active Active
2009
- 2009-07-30 IL IL200153A patent/IL200153A/en active IP Right Grant
2014
- 2014-06-17 CY CY20141100437T patent/CY1115227T1/el unknown

Also Published As

Publication number	Publication date
EP2114951B1 (en)	2014-04-09
HK1138262A1 (en)	2010-08-20
RU2009135810A (ru)	2011-04-10
NZ578804A (en)	2012-04-27
CA2676933C (en)	2015-09-29
DK2114951T3 (da)	2014-06-23
US20100099688A1 (en)	2010-04-22
JP5501770B2 (ja)	2014-05-28
HRP20140585T1 (hr)	2014-09-12
CY1115227T1 (el)	2017-01-04
KR101571654B1 (ko)	2015-11-25
JP2010519332A (ja)	2010-06-03
PT2114951E (pt)	2014-07-17
RS53407B (sr)	2014-10-31
WO2008104175A2 (en)	2008-09-04
AU2008221121A1 (en)	2008-09-04
CA2676933A1 (en)	2008-09-04
ES2478670T3 (es)	2014-07-22
AU2008221121B2 (en)	2013-10-03
BRPI0807749B1 (pt)	2021-01-05
IL200153A0 (en)	2010-04-15
US8338431B2 (en)	2012-12-25
IL200153A (en)	2016-11-30
MX2009009238A (es)	2009-09-08
EP2114951B9 (en)	2015-09-02
RU2495043C2 (ru)	2013-10-10
MY150075A (en)	2013-11-29
EP2114951A2 (en)	2009-11-11
SI2114951T1 (sl)	2014-08-29
PL2114951T3 (pl)	2014-10-31
KR20090126252A (ko)	2009-12-08
WO2008104175A3 (en)	2009-01-29
BRPI0807749B8 (pt)	2022-09-06

Similar Documents

Publication	Publication Date	Title
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0912111A2 (pt)	2015-10-06	composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0817525A2 (pt)	2014-11-18	Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0822398A2 (pt)	2014-11-18	Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0716092A2 (pt)	2013-09-17	composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
BRPI1011593A2 (pt)	2016-03-22	"combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos."
BRPI0816175A2 (pt)	2015-02-24	Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BR112013026341A2 (pt)	2019-09-24	composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
LT2878297T (lt)	2020-07-10	Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0717753A2 (pt)	2013-10-22	Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
BR112014004181A2 (pt)	2017-06-13	composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia

Legal Events

Date	Code	Title	Description
2018-03-20	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-01-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-02-11	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-07-14	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-11-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-01-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-03-15	B25A	Requested transfer of rights approved	Owner name: UNION THERAPEUTICS A/S (DK)
2022-08-23	B25L	Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled	Owner name: LEO PHARMA A/S (DK) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2671 DE 15/03/2022 POR TER SIDO INDEVIDA.
2022-09-06	B25A	Requested transfer of rights approved	Owner name: UNION THERAPEUTICS A/S (DK)
2025-12-23	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 18A ANUIDADE.
2026-04-22	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2868 DE 23-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.